AstraZeneca PLC’s Iressa (gefitinib) took a convoluted path to the US market, spanning 20 years and two new drug applications (NDAs).
Iressa also holds a unique position in the Pink Sheet’s Drug Review Profile series as the only product we have...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?